We are live on ! Find out more
PLX icon

Protalix BioTherapeutics
PLX

63 hedge funds and large institutions have $11.9M invested in Protalix BioTherapeutics in 2024 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 21 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

265% more call options, than puts

Call options by funds: $62K | Put options by funds: $17K

1.01% less ownership

Funds ownership: 13.86% → 12.85% (-1%)

5% less funds holding

Funds holding: 66 → 63 (-3)

24% less repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 21

27% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 11

34% less capital invested

Capital invested by funds: $18M → $11.9M (-$6.08M)

Holders
63
Holders Change
-3
Holders Change %
-4.55%
% of All Funds
0.91%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
16
Reduced
21
Closed
11
Calls
$62K
Puts
$17K
Net Calls
+$45K
Net Calls Change
-$789K

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$238K
2
VF
Virtu Financial
New York
+$235K
3
TSS
Two Sigma Securities
New York
+$61K
4
Citadel Advisors
Citadel Advisors
Florida
+$56.4K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$44.1K

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$487K
2
BlackRock
BlackRock
New York
-$220K
3
DA
Denali Advisors
California
-$169K
4
Bank of America
Bank of America
North Carolina
-$132K
5
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
-$126K
Name Holding Trade Value Shares
Change 		Change in
Stake
Franklin Resources
26
Franklin Resources
California
$42.3K – – –
AIG
27
American International Group
New York
$42K +$517 +346 +1%
JP Morgan Chase
28
JP Morgan Chase
New York
$41K -$16.7K -11,216 -26%
Jane Street
29
Jane Street
New York
$36.4K +$143 +96 +0.3%
VOYA Investment Management
30
VOYA Investment Management
Georgia
$34K -$3.35K -2,242 -8%
CPA
31
Capital Performance Advisors
California
$33.1K +$423 +283 +1%
Invesco
32
Invesco
Georgia
$32.6K -$1.46K -976 -4%
Verition Fund Management
33
Verition Fund Management
Connecticut
$29.6K +$35K +23,465 New
AllianceBernstein
34
AllianceBernstein
Tennessee
$29.5K – – –
Wells Fargo
35
Wells Fargo
California
$29.4K +$5.13K +3,439 +17%
SG Americas Securities
36
SG Americas Securities
New York
$27K -$19.6K -13,139 -38%
ACA
37
Aptus Capital Advisors
Alabama
$24.7K +$1.64K +1,099 +6%
Squarepoint
38
Squarepoint
New York
$22.4K +$26.6K +17,815 New
T. Rowe Price Associates
39
T. Rowe Price Associates
Maryland
$21K – – –
KAS
40
Kestra Advisory Services
Texas
$20.2K +$6.72K +4,500 +39%
Lido Advisors
41
Lido Advisors
California
$19.6K – – –
FI
42
Finivi Inc
Massachusetts
$18.3K – – –
Citigroup
43
Citigroup
New York
$16K +$1.76K +1,180 +10%
ProShare Advisors
44
ProShare Advisors
Maryland
$15.3K +$1.74K +1,168 +11%
AS
45
Altshuler Shaham
Israel
$15.3K – – –
Millennium Management
46
Millennium Management
New York
$13.2K +$15.7K +10,484 New
HIM
47
Harbour Investment Management
Washington
$12.7K – – –
California State Teachers Retirement System (CalSTRS)
48
California State Teachers Retirement System (CalSTRS)
California
$8.56K -$6.15K -4,122 -38%
TWC
49
TD Waterhouse Canada
Ontario, Canada
$7.44K – – –
Legal & General Group
50
Legal & General Group
United Kingdom
$6.75K – – –
1
2
3

PLX Hedge Fund Activity: Q1 2024 in Review

63 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Protalix BioTherapeutics (PLX) for Q1 2024, worth a combined $11.9M — down 34% from $18M a quarter earlier.

Sellers outnumbered buyers: 11 funds closed out of PLX and 8 opened new positions — a net loss of 3 holders — while 21 trimmed existing stakes and 16 added.

The largest buyer was Renaissance Technologies, adding an estimated $238K. The largest seller was Morgan Stanley, cutting an estimated $487K.

  • 63 institutional investors held Protalix BioTherapeutics (PLX) as of Q1 2024, down from 66 in Q4 2023.
  • Funds reported $11.9M of Protalix BioTherapeutics stock for Q1 2024, down 34% quarter-over-quarter.
  • 8 funds opened new Protalix BioTherapeutics positions in Q1 2024 and 11 closed out, a net change of -3 holders.
  • The largest Protalix BioTherapeutics buyer in Q1 2024 was Renaissance Technologies, an estimated $238K added.
  • The largest Protalix BioTherapeutics seller in Q1 2024 was Morgan Stanley, an estimated $487K sold.

Based on aggregated 13F filings for Q1 2024.